Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Equity

Summit Therapeutics (SMMT) Return on Sales (2016 - 2023)

Summit Therapeutics filings provide 8 years of Return on Sales readings, the most recent being 26.83% for Q2 2023.

  • Quarterly Return on Sales fell 2629.0% to 26.83% in Q2 2023 from the year-ago period, while the trailing twelve-month figure was 26.83% through Jun 2023, down 2643.0% year-over-year, with the annual reading at 1.12% for FY2022, 63.0% down from the prior year.
  • Return on Sales hit 26.83% in Q2 2023 for Summit Therapeutics, down from 12.9% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.13% in Q1 2019 and bottomed at 26.83% in Q2 2023.
  • Average Return on Sales over 5 years is 2.86%, with a median of 0.77% recorded in 2022.
  • The largest annual shift saw Return on Sales surged 374bps in 2022 before it crashed -2629bps in 2023.
  • Summit Therapeutics' Return on Sales stood at 0.68% in 2019, then decreased by -7bps to 0.73% in 2020, then tumbled by -48bps to 1.08% in 2021, then increased by 5bps to 1.02% in 2022, then plummeted by -2524bps to 26.83% in 2023.
  • Per Business Quant, the three most recent readings for SMMT's Return on Sales are 26.83% (Q2 2023), 12.9% (Q1 2023), and 1.02% (Q4 2022).